Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
Episodes
Monday Aug 14, 2023
Monday Aug 14, 2023
touchPANEL DISCUSSION for touchONCOLOGY
Listen to three breast cancer experts discuss the expanding targeted treatment options for HER2-negative metastatic breast cancer, with a focus on approved and emerging antibody drug conjugates and considerations for their use in clinical practice.
The experts
- Prof. Giuseppe Curigliano, University of Milan, Milan, Italy
- Prof. Hope Rugo, University of California, San Francisco, CA, USA
- Prof. Peter Schmid, Barts Cancer Institute, London, UK
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Gilead Sciences, Inc. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/new-and-emerging-agents-in-her2negative-mbc
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.